Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7002 results

Sort By:

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Study ID: NCT06958107
Start Date: 2025-08-21
End Date: 2030-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

Non-Metastatic and Resectable

Metastatic and Un-resectable

No evidence of disease, under surveillance

ALT or WDLS

Sponsor

Wake Forest University Health Sciences

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus (EBV)-Associated Diseases

Study ID: NCT04554914
Start Date: 2021-07-14
End Date: 2028-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

190

Intervention / Treatment

Tabelecleucel

Sponsor

Pierre Fabre Medicine

Source: clinicaltrials.gov

Share:
Add to list

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Study ID: NCT06453044
Start Date: 2024-09-09
End Date: 2028-03-14
Study Type

Interventional

Study Phase

Phase2

No. of Participants

41

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Mosunetuzumab

Polatuzumab Vedotin

Positron Emission Tomography

Administration Questionnaire

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Study ID: NCT06123338
Start Date: 2024-02-01
End Date: 2027-11-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

49

Intervention / Treatment

Pembrolizumab

Trastuzumab

Oxaliplatin

Capecitabine

5-Fluorouracil

Docetaxel

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Study ID: NCT04923126
Start Date: 2021-06-21
End Date: 2031-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

132

Intervention / Treatment

Mirdametinib

Sponsor

St. Jude Children's Research Hospital

Source: clinicaltrials.gov

Share:
Add to list

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Study ID: NCT06297226
Start Date: 2024-03-21
End Date: 2032-06-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

230

Intervention / Treatment

Arlocabtagene Autoleucel

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Source: clinicaltrials.gov

Share:
Add to list

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Study ID: NCT06425926
Start Date: 2024-05-09
End Date: 2026-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

117

Intervention / Treatment

GIM-531

Anti-PD-1 monoclonal antibody

Sponsor

Georgiamune Inc

Source: clinicaltrials.gov

Share:
Add to list

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Study ID: NCT05879926
Start Date: 2023-08-31
End Date: 2034-07
Study Type

Interventional

Study Phase

Phase3

No. of Participants

3960

Intervention / Treatment

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Sponsor

NRG Oncology

Source: clinicaltrials.gov

Share:
Add to list

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Study ID: NCT06526793
Start Date: 2024-11-27
End Date: 2029-06-14
Study Type

Interventional

Study Phase

Phase2

No. of Participants

240

Intervention / Treatment

Surowatamig

Sponsor

AstraZeneca

Source: clinicaltrials.gov

Share:
Add to list

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Study ID: NCT02366819
Start Date: 2014-12-11
End Date: 2026-06-08
Study Type

Interventional

Study Phase

Phase4

No. of Participants

36

Intervention / Treatment

Oxaliplatin

Leucovorin calcium

Irinotecan Hydrochloride

Fluorouracil

Conventional Surgery

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list